QUICK MENU

오늘 본 상품

  • 제품명이 노출되는 영역입니다.
    Fragile X
    US$ 9,995
1 /
TOP
Deeper Insights Lead to Success
We are striving to secure our standing as an Intelligence Information Platform that supports clients’
decision-making and promoting direction of future business, with providing trustful global market insights.
2025-02-14 Fragile X Syndrome Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2030
Vertical lnadustry/Pharmacy
GlobalData

License Type

Single User
US$ 9,995
Multi-users
US$ 19,990
Enterprise
US$ 29,985

< Key Hightlight >

This report covers the US and Germany and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030.

The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030.
The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry, these products will be Harmony Biosciences’ Zygel and Shionogi’s zatolmilast. The sales of high-priced pipeline agents Zygel and zatolmilast represent the most impactful drivers of growth.

Scope
Overview of Fragile X Sundrome (FXS), including epidemiology, symptoms, diagnosis, and disease management.

Annualized FXS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the FXS market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for FXS. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the US and German FXS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the US and German FXS therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FXS therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

상품 선택옵션 1 개, 추가옵션 0 개

배송비결제 주문시 결제
Inquiry

관련 보고서 추천